GlassScriptPhysician profile
Amber Mayberry
NPI 1689006942
$4,064.94
in general payments reported to CMS, 2019-2025
19 companies · $886 in 2025
The $886 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $300 · 2021: $380 · 2022: $523 · 2023: $951 · 2024: $633 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $789.61 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $688.19 | 2020-2025 | Acthar |
| Alcon Vision LLC | $557.17 | 2019-2025 | Dailies Total1, Clareon, Dailies Aqua Comfort Plus |
| Bausch & Lomb Americas INC. | $460.53 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $271.69 | 2021-2023 | |
| Allergan, INC. | $246.33 | 2019-2022 | |
| Abbvie INC. | $189.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $145.86 | 2019-2024 | |
| Dompe US, INC. | $131.18 | 2019-2025 | Oxervate |
| Glaukos Corporation | $121.47 | 2020 | |
| Sight Sciences, INC. | $98.94 | 2020 | |
| Oyster Point Pharma, INC. | $77.59 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Enterprises LLC | $72.24 | 2019 | |
| Coopervision INC. | $66.44 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens |
| Shire North American Group INC | $57.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $31.25 | 2022 | |
| Astellas Pharma US INC | $30.41 | 2024 | Izervay |
| Amgen INC. | $17.57 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Mayberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.